Work

Supplementary Table S3 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

Year: 2023

Type: supplementary-materials

Abstract: Correlative analysis of PFS and OS with the expression of biomarkers using the 75th percentile of marker distribution as cutpoint: Total IR, IR-A, IR-B, and IGF-1R in pooled group and arm A

DOI: 10.1158/1078-0432.22458788

Authors: William J. Gradishar, Denise A. Yardley, Rachel Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Ruslan Novosiadly, Amelie Forest, Tuan S. Nguyen, Jan Cosaert, Dmitri Grebennik, Paul Haluska

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361884485

Cites:

Cited by:

Related to: 10